Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders
dc.contributor.author | Schwartz, Stanley A. | en_US |
dc.date.accessioned | 2006-09-11T15:20:45Z | |
dc.date.available | 2006-09-11T15:20:45Z | |
dc.date.issued | 1990-03 | en_US |
dc.identifier.citation | Schwartz, Stanley A.; (1990). "Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders." Journal of Clinical Immunology 10(2): 81-89. <http://hdl.handle.net/2027.42/44840> | en_US |
dc.identifier.issn | 0271-9142 | en_US |
dc.identifier.issn | 1573-2592 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/44840 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2187017&dopt=citation | en_US |
dc.description.abstract | The weight of evidence from numerous clinical studies supports the use of IVIG, particularly at higher doses, in the treatment of a wide range of autoimmune disorders. Extensive experience has documented the safety of IVIG therapy but its present relatively high cost necessitates firmly establishing its efficacy. There is an acute need to define those disease states where IVIG is indicated and effective. Large-scale, possibly multicentered, clinical trials employing rigorous controls will resolve these questions. Concurrent fundamental immunologic studies will elucidate the mechanisms underlying the clinical effects. We are experiencing an exciting new era of effective immunotherapies and intravenous gamma-globulin preparations have already secured an important place in the therapeutic armamentarium. While one must guard against unsubstantiated applications, critical exploration of new uses for this unique product is warranted. | en_US |
dc.format.extent | 1199248 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Infectious Diseases | en_US |
dc.subject.other | Autoimmunity | en_US |
dc.subject.other | Medical Microbiology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Immunology | en_US |
dc.subject.other | Internal Medicine | en_US |
dc.subject.other | Intravenous Immunoglobulin | en_US |
dc.subject.other | Immunomodulation | en_US |
dc.title | Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Pediatrics, Microbiology/Immunology, and Epidemiology, The University of Michigan, 48109-2029, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 2187017 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/44840/1/10875_2004_Article_BF00918189.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00918189 | en_US |
dc.identifier.source | Journal of Clinical Immunology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.